Cell and Gene Therapy Market Size, Share, and Outlook, H2-2025 Report- By Type (Cell Therapy, Gene Therapy), By Gene Type, Gene silencing, Cell replacement, Gene augmentation, Others), By Cell Type (T-Cells, Stem Cells, Other), By Application (Oncology, D

Cell and Gene Therapy Market Outlook
The global Cell and Gene Therapy Market Size is valued at $10.5 Billion in 2025 and is forecast to reach $34.7 Billion in 2032 at a CAGR of 18.6%.
The Cell and Gene Therapy Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Cell and Gene Therapy Market segments across 22 countries from 2021 to 2032. Key segments covered include By Type (Cell Therapy, Gene Therapy), By Gene Type, Gene silencing, Cell replacement, Gene augmentation, Others), By Cell Type (T-Cells, Stem Cells, Other), By Application (Oncology, Dermatology, Musculoskeletal, Genetic Disorders, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.

Cell and Gene Therapy Market Insights, 2025
In 2025, the cell and gene therapy sector continues to expand rapidly, with approvals in hematologic malignancies, rare genetic disorders, and ophthalmology marking a shift toward more routine clinical use. CAR-T therapies now include off-the-shelf allogeneic versions that reduce manufacturing time and expand patient access, while in vivo gene-editing approaches using CRISPR and base-editing platforms are entering pivotal trials for conditions such as sickle cell disease and transthyretin amyloidosis. Manufacturing innovation is a major focus, with modular, closed-system production units enabling decentralized manufacturing near treatment centers to address supply bottlenecks. Regulatory frameworks in the U.S., EU, and Asia are adapting to allow rolling submissions and accelerated pathways for transformative therapies, while payers are piloting milestone-based reimbursement models tied to long-term efficacy. Post-marketing surveillance integrates registry-based safety tracking and genomic monitoring to assess durability and off-target effects over years.

Five Trends Shaping the Global Cell and Gene Therapy Market in 2025 and Beyond
The global Cell and Gene Therapy Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.

What are the Biggest Opportunities for Growth in the Cell and Gene Therapy Industry?
The Cell and Gene Therapy Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Cell and Gene Therapy Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.

Cell and Gene Therapy Market Segment Insights
The Cell and Gene Therapy Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Type (Cell Therapy, Gene Therapy), By Gene Type, Gene silencing, Cell replacement, Gene augmentation, Others), By Cell Type (T-Cells, Stem Cells, Other), By Application (Oncology, Dermatology, Musculoskeletal, Genetic Disorders, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.

Cell and Gene Therapy Industry Value Chain
The chapter identifies potential companies and their operations across the global Cell and Gene Therapy Industry ecosystem. It assists decision-makers in evaluating global Cell and Gene Therapy Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.

Scenario Analysis and Forecasts
Strategic planning in the Cell and Gene Therapy Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.

Asia Pacific Cell and Gene Therapy Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Cell and Gene Therapy Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.

United States Cell and Gene Therapy Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Cell and Gene Therapy Market.

Europe Cell and Gene Therapy Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Cell and Gene Therapy Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Cell and Gene Therapy Industry competitiveness. The report analyses the key Cell and Gene Therapy Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.

Latin American Cell and Gene Therapy Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Cell and Gene Therapy Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.

Middle East and Africa Cell and Gene Therapy Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Cell and Gene Therapy Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.

Competitive Landscape – How Cell and Gene Therapy Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Cell and Gene Therapy Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Alnylam Pharmaceuticals Inc, Amgen Inc, Biogen Inc, Bluebird bio Inc, Bristol Myers Squibb Co., Castle Creek Biosciences Inc, CORESTEM Inc, Cytori Therapeutics Inc, Dendreon Pharmaceuticals LLC, Ferring BV, Gilead Sciences Inc, Helixmith Co. Ltd, Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd, Kolon TissueGene Inc, Novartis AG, Orchard Therapeutics Plc, Pfizer Inc, Sibiono GeneTech Co. Ltd, Vericel Corp. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.

Cell and Gene Therapy Market Scope
Leading Segments
By Type
Cell Therapy
Gene Therapy
By Gene Type
Gene silencing
Cell replacement
Gene augmentation
Others
By Cell Type
T-Cells
Stem Cells
Other
By Application
Oncology
Dermatology
Musculoskeletal
Genetic Disorders
Others

Leading Companies
Alnylam Pharmaceuticals Inc
Amgen Inc
Biogen Inc
Bluebird bio Inc
Bristol Myers Squibb Co.
Castle Creek Biosciences Inc
CORESTEM Inc
Cytori Therapeutics Inc
Dendreon Pharmaceuticals LLC
Ferring BV
Gilead Sciences Inc
Helixmith Co. Ltd
Human Stem Cells Institute
JCR Pharmaceticals Co. Ltd
Kolon TissueGene Inc
Novartis AG
Orchard Therapeutics Plc
Pfizer Inc
Sibiono GeneTech Co. Ltd
Vericel Corp

Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Reasons to Buy the Report

Make informed decisions with 12-year forecasts across 22 countries and multiple market segments.

Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry.

Gain insights into the competitive landscape, including company profiles, financials, and strategic moves.

Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations.

Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade.

Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions.

Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.

Show more